Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: A rare case of ocular giant cell arteritis with bilateral orbital inflammation and diagnostic challenges.

Frontiers in neurology·2026
Same author

Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study.

Aging·2026
Same author

Anthropogenic Vessel Strike as a Threat to Spotted Seals (<i>Phoca largha</i>) in Korean Waters: A Multimodal Forensic Investigation.

Animals : an open access journal from MDPI·2026
Same author

Early Choroidal Microvascular Alterations Detected by Optical Coherence Tomography 3 Angiography in Diabetic Eyes Without Retinopathy.

Korean journal of ophthalmology : KJO·2026
Same author

IFI35 suppresses the transcription of hepatitis B virus cccDNA minichromosome via promoting HNF4α proteasomal degradation.

Journal of biomedical science·2026
Same author

Platelet proteomic signatures of amyloid β-positive mild cognitive impairment and Alzheimer's disease.

Molecular brain·2026

Related Experiment Video

Updated: May 28, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression.

Yeon Ji Park1,2, Jae Won Oh3, Hyewon Chung4

  • 1Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

Molecular Oncology
|February 12, 2025
PubMed
Summary

Immunosuppressive breast cancers, unlike benign tumors, alter blood proteins. Key immune proteins like osteopontin may predict cancer progression and patient outcomes.

Keywords:
biomarkerimmunosuppressive cancermyeloid‐derived suppressor cellsplasmaproteomics

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.4K

Related Experiment Videos

Last Updated: May 28, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.4K

Area of Science:

  • Oncology
  • Immunology
  • Proteomics

Background:

  • Immune status significantly influences cancer progression and treatment efficacy.
  • Identifying biomarkers for cancer-induced immunosuppression is crucial for effective management.

Purpose of the Study:

  • To investigate plasma proteome alterations in immunosuppressive breast cancer models.
  • To identify potential biomarkers predicting systemic immunosuppression and myeloid-derived suppressor cells (MDSCs).

Main Methods:

  • Utilized mouse models of syngeneic benign (67NR) and malignant (4T1) breast tumors.
  • Collected and analyzed plasma samples from naive and tumor-bearing mice using liquid chromatography-mass spectrometry (LC-MS).

Main Results:

  • Malignant 4T1 tumors induced systemic immunosuppression with significant myeloid-derived suppressor cell generation by day 7.
  • LC-MS identified 1086 proteins; 27 were specific to 4T1 tumors.
  • Osteopontin, lactotransferrin, calreticulin, and peroxiredoxin 2 were identified as potential biomarkers for MDSC-producing breast cancer.

Conclusions:

  • MDSC-producing immunosuppressive cancers exhibit distinct plasma proteomes.
  • Identified biomarkers like osteopontin and peroxiredoxin 2 correlate with poor survival and recurrence in triple-negative breast cancer patients.
  • Findings offer insights into cancer immune status and potential diagnostic markers.